Perinal Cutaneous Spray

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/03/15

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 31/8/2018

Click on this link to Download PDF directly

Dermal Laboratories Limited

Dermal Laboratories Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Anhydrol Forte 20% w/v Cutaneous Solution Active Ingredients Aluminium Chloride Hexahydrate
Medicine Name Betacap Scalp Application 0.1% w/w Cutaneous Solution Active Ingredients Betamethasone Valerate
Medicine Name Capasal Therapeutic Shampoo Active Ingredients Coconut Oil, Distilled Coal Tar, Salicylic Acid
Medicine Name Dioderm 0.1% w/w Cream Active Ingredients Hydrocortisone
Medicine Name Dithrocream Active Ingredients Dithranol
Medicine Name Emulsiderm Emollient Bath Additive/Cutaneous Emulsion Active Ingredients Benzalkonium Chloride, Isopropyl Myristate, Liquid Paraffin
Medicine Name Exterol 5% w/w Ear Drops, Solution Active Ingredients Urea Hydrogen Peroxide
Medicine Name Glutarol 10% w/v Cutaneous Solution Active Ingredients Glutaraldehyde
Medicine Name Ibugel 5% w/w Gel Active Ingredients Ibuprofen
Medicine Name Nicam 4% w/w Gel Active Ingredients Nicotinamide
Medicine Name Perinal Cutaneous Spray Active Ingredients Hydrocortisone, Lidocaine Hydrochloride
Medicine Name Psoriderm Cream Active Ingredients Distilled Coal Tar
Medicine Name Psoriderm Emulsion 40% w/v Bath Additive Active Ingredients Distilled Coal Tar
Medicine Name Psoriderm Scalp Lotion Shampoo Active Ingredients Distilled Coal Tar
Medicine Name Salactol Collodion Active Ingredients Lactic Acid, Salicylic Acid
Medicine Name Salatac Gel Active Ingredients Lactic Acid, Salicylic Acid
1 - 0 of 16 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 31 August 2018 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

File format updated to PDF

Updated on 10 August 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 10 August 2015 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.8 Undesirable effects, in the HPRA address "IRL - Dublin" has been updated to "IRL - Dublin 2"

Updated on 11 March 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 11 March 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.8 Undesirable effects, the following text has been added:

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important.  It allows continued monitoring of the benefit/risk balance of the medicinal product.  Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin; Tel: +353 1 6764971; Fax: +353 1 6762517.  Website: www.hpra.ie; E-mail:medsafety@hpra.ie.



In section 10 Date of revision of the text, the date has changed to "March 2015"

Updated on 11 March 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Removal/change of distributor

Updated on 18 March 2014 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.1 (Therapeutic indications) the text has changed to:
"Perinal is indicated for the symptomatic relief of anal and perianal pruritus, pain and inflammation such as associated with haemorrhoids, anal fissures or loose stools.  Perinal is indicated in adults, children and adolescents.  Use in children under 14 years is recommended only under medical supervision (see section 4.2)."

In section 4.2 (Posology and method of administration) the text has changed to:
"Spray once over the affected area up to three times daily, depending on the severity of the condition, or as recommended by the doctor.
The same dosage schedule applies to all age groups.
Paediatric population
Perinal is indicated in the paediatric population however special care should be exercised before treating children and adolescents aged under 14 years, to exclude any other underlying medical conditions.
"

In section 4.3 (Contra-indications) the text has changed to:
"Hypersensitivity to the active substances or to any of the excipients in section 6.1.
Not to be used on broken or infected skin.
"

In section 10 (Date of revision of the text) the date has changed to:
"February 2014"

Updated on 28 January 2013 PIL

Reasons for updating

  • Change to drug interactions
  • Change to date of revision

Updated on 14 February 2012 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 10 (Date of revision of the text) the date has changed to "January 2012".

Updated on 13 February 2012 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 13 May 2011 PIL

Reasons for updating

  • Change of trade or active ingredient name

Updated on 2 December 2010 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 6.1 (List of excipients) there is a change of name from "cetomacrogol 1000" to "macrogol cetostearyl ether (cetomacrogol)"

In section 10 (date of revision of the text) the date has changed to "November 2010"

Updated on 19 January 2009 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 1 (Name of the Medicinal Product) : the name has changed to "Perinal Cutaneous Spray"
 
In section 10 (Date of Revision of the Text) : the date has changed to "December 2008"

Updated on 1 December 2008 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.3 (Contraindications) the text has changed to:

Not to be used if sensitive to lidocaine or any other of the ingredients.  Not to be used on broken or infected skin.  Do not use on children under the age of 14 years without medical supervision.

 
In section 4.4 (Special warnings and precautions for use) the text has changed to:
 
Perinal Spray is intended for use for limited periods and so should not be used continuously for longer than 7 days without medical advice.  Patients should be instructed to seek medical advice if they experience persistent pain or bleeding from the anus, especially where associated with a change in bowel habit, if the stomach is distended or if they are losing weight.  Prompt medical treatment may be very important under such circumstances.

Not to be used internally (inside the anus), or anywhere other than the anal area.

Medical supervision is required if used in conjunction with other medicines containing steroids, owing to possible additive effects.

Perinal Spray should be kept away from the eyes, nose and mouth.
 
 
In section 10 (Date of revision of the text) the text has changed to:
 
October 2008.

Updated on 13 August 2007 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 1 August 2007 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Update to section 4.6, pregnancy and lactation, in line with UK SPC.
 
Update to section 5.1, pharmacodynamic properties, to include ATC code.
 
Amends to sections 6.2, incompatibilities, and 6.6, special precautions.
 
Section 9 - renewal date changed to 5 June 2007.

Updated on 1 August 2007 PIL

Reasons for updating

  • Change of trade or active ingredient name

Updated on 18 August 2006 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 - Posology and method of administration:  Text "The spray will operate in any orientation" deleted.
 
Section 4.4 - Special warnings and precautions for use: Text "Keep all medicines out of the reach of children" deleted.
 
Section 5.1 - Pharmacodynamic properties: Text "On application, finger contact with the affected area can be avoided which makes for improved hygiene, and lessens the risk of infection" deleted.
 
Section 5.2 - Pharmacokinetic properties: Text "Because the preparation is a clear solution, it is entirely homogeneous, and the availability of the active ingredients is optimal" deleted.
 
 

Updated on 27 July 2005 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 8 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 13 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)